David E. Gutstein

Vice President, Strategic Program Direction – Hematology Translational & Clinical Sciences
Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States

Presentation(s):

• PB0134 - A novel method for measuring ex vivo intrinsic pathway-triggered thrombin generation in the development of REGN9933, a monoclonal antibody targeting factor XI

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0384 - Antibodies against factor XI/factor XIa effectively anticoagulate without increasing bleeding risk in cynomolgus monkeys

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0235 - Trial-in-progress: A two-part open-label study of an in vivo CRISPR/Cas9-based coagulation factor IX targeted gene insertion therapy (REGV131-LNP1265), in participants with hemophilia B (BEYOND-9)

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0537 - Development of novel gene editing lexicon for hemophilia: methodology and results

  Monday, June 24, 2024
  13:45 – 14:45 ICT